CTIS2022-500678-33-00进行中（未招募）1 期
PLATFORM-COVID study; Platform randomised trial of treatments for COVID-19 in general practice - NL79504.068.21
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Participant is willing and able to give informed consent for participation in the study; •Participant is willing to comply with all trial procedures; •A positive test for SARS-Co-V2 infection (can be PCR, LAMP, antigen or self-test) [10], which was taken fewer than 15 days ago, AND the participant is unwell with symptoms of COVID-19. These symptoms may include, but are not limited to, shortness of breath, general feeling of being unwell, muscle pain, diarrhoea, vomiting, fever and cough, and they must have had them for fewer than 15 days. •Patients aged =18-64 years with any of the following listed comorbidities (which makes them more vulnerable, and for which they receive or have received treatment): •Chronic disruptions and function loss of the airways and lungs, which are severe enough to be treated by a pulmonologist. •Chronic disorder of the heart function, which makes the patient eligible for the influenza vaccination. •Diabetes mellitus: poorly controlled diabetes or diabetes with secondary comorbidities. •Severe kidney dysfunction which requires dialysis or kidney transplantation. •Reduced immunity to infections due to auto-immune diseases, after organ or stemcel transplantation, hematological diseases, Asplenia, severe immune disorders present at birth or developed later in life, which require treatment or during and within 3 months of chemotherapy. •Untreated HIV-infection or an HIV infection with a CD4 higher than 200. •Severe liver disease in Child-Pugh classification B or C. •Morbid obesity (BMI>40). •Patients aged =65
排除标准
- •Patients currently admitted to hospital •Almost recovered (generally much improved and symptoms now mild or almost absent) •Known hypersensitivity to montelukast •Concomitant use of montelukast
研究者
相似试验
进行中（未招募）
1 期
Treatments of COVID-19 in primary care in the NetherlandsPatients with symptomatic COVID-19 in the community and in primary care, who are at higher risk of a complicated illness course.MedDRA version: 23.0Level: PTClassification code: 10084268Term: COVID-19 Class: 100000004862CTIS2022-501559-99-00Maastricht University682
已完成
不适用
A study to evaluate diagnostic tests used at the point of care for improving antibiotic prescribing for patients with respiratory tract infections in primary care in EuropeCommunity-acquired acute respiratory tract infectionRespiratoryISRCTN13336322niversity of Oxford2,649
进行中（未招募）
1 期
Platform Randomised trial of INterventions against COVID-19 In older peopleSuspected COVID-19MedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862EUCTR2020-001209-22-GBniversity of Oxford / Clinical Trials and Research Governance3,000
进行中（未招募）
1 期
Window-of-opportunity clinical trials platform for evaluation of novel treatment strategies in renal cell cancer.Surgically resectable renal cell cancer (Stage M0/M1)MedDRA version: 21.0Level: PTClassification code 10038389Term: Renal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003056-21-GBCambridge University Hospitals NHS Foundation Trust and the University of Cambridge76
招募中
2 期
A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non Small Cell Lung CancerNSCLClung cancerNL-OMON51766GlaxoSmithKline20